Tag: AACR
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting...
-- IL-13 Superkines provide a versatile strategy for targeted delivery of anti-cancer agents to IL-13Rα2, which is overexpressed in many solid tumors but...
New analysis of Phase II data at AACR assesses ImaginAb’s investigational...
LOS ANGELES, April 14, 2023 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical...
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual...
Repare Therapeutics Inc. ("Repare" or the "Company") RPTX, a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials...
Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at...
CAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on...
C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader...
– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including...
Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session...
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated ...
F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated...
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660...
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing...
New Clinical Responses for AGEN1181 Presented at AACR
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically...
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021...
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature-...